Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Related Articles
New Ventures To Use AI To Target Heart Disease
Innovator News: Mayo Clinic announced a new technology platform and launched two new companies April 14 that promise to improve doctors’ ability to spot disease early by connecting data from…April 24, 2021
Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data
FIERCE Biotech: An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable,…May 09, 2022
Mayo-developed AI detects heart condition from Apple Watch ECGs
Modern Healthcare: An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference…April 30, 2022
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022